Precision Medicine in Oncology®

David O'Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses folate-receptor alpha as a biomarker in ovarian cancer.

Dara L. Aisner, MD, PhD, associate professor in the department of Pathology at the University of Colorado School of Medicine, discusses the limitations of molecular profiling.

Recent positive clinical trial data have provided the oncology community with several sequencing strategies for patients with EGFR-mutant non-small cell lung cancer.

The use of frontline versus second-line tyrosine kinase inhibitor use is controversial in many oncogene-driven non-small cell lung cancers.

Heather Wakelee, MD, associate professor of medicine (oncology) at the Stanford University Medical Center, discussed the latest therapeutic developments in EGFR-mutant non-small cell lung cancer.

Leonid Shunyakov, MD, hematologist/oncologist, Central Care Cancer Center, discusses how genomics have impacted personalized therapy in oncology.

Immunotherapy should be given as a tailored, not blanket, treatment approach, especially for patients with lung cancer, according to Giorgio Scagliotti, MD, PhD.

Several novel targeted therapies are emerging for a growing number of driver mutations in lung cancer, with multiple targeted agents now confirmed standards of care.

Leonid Shunyakov, MD, hematologist/oncologist, Central Care Cancer Center, discusses the impact of next-generation sequencing (NGS) in oncology.

Maurie Markman, MD, defines precision medicine in oncology.

Advanced sequencing techniques have revolutionized the understanding of how cancer has developed and enabled treatment selection based on genomic characterization of the tumor.

Antibody-drug conjugates represent a targeted class of agents with an improved therapeutic index over traditional chemotherapy in the treatment of non-Hodgkin lymphoma.

Rapid progress in the development of BET inhibitors has created a surge of enthusiasm.

Amid an explosion of innovation and discovery in the oncology field, researchers are finding it increasingly difficult to recruit enough patients for clinical trials.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of osimertinib as a first-line treatment for patients with non–small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutations.